[Experience in the treatment of metastatic breast carcinoma with norethisterone acetate in a clinical study].
Twenty-nine patients with progressive advanced carcinoma of the breast were treated with 40 mg/day norethisterone acetate orally in this clinical trial. 27 of 29 patients were evaluable for response to the drug. One patient achieved a partial response (duration 2 months), 6 had a stable disease (median duration 7.6 months) and 20 developed a progressive disease on treatment. There was a high rate of liver toxicity in 23 patients [grade 3 and 4 according to WHO (1)]. The literature on norethisterone acetate is reviewed and compared with present results. The role of progestogenic agents in treatment of advanced mammary carcinoma is discussed.
Stier
G
G
Zentralinstitut für Krebsforschung der Akademie der Wissenschaften der DDR, Robert-Rössle-Institut, Berlin-Buch.
Gürtler
R
R
Schmidt
U M
UM
D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008593:Menopause / Q000187:drug effects; D009362:Neoplasm Metastasis; D009640:Norethindrone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D012074:Remission Induction; D013997:Time Factors
D000077563:Norethindrone Acetate; D009640:Norethindrone
Erfahrungen bei der Behandlung des metastasierten Mammakarzinoms mit Noräthisteronacetat im Rahmen einer klinischen Studie.